1. Home
  2. GNLX vs ASRT Comparison

GNLX vs ASRT Comparison

Compare GNLX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNLX
  • ASRT
  • Stock Information
  • Founded
  • GNLX 2001
  • ASRT 1995
  • Country
  • GNLX United States
  • ASRT United States
  • Employees
  • GNLX N/A
  • ASRT N/A
  • Industry
  • GNLX Biotechnology: Pharmaceutical Preparations
  • ASRT Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNLX Health Care
  • ASRT Health Care
  • Exchange
  • GNLX Nasdaq
  • ASRT Nasdaq
  • Market Cap
  • GNLX 85.0M
  • ASRT 85.1M
  • IPO Year
  • GNLX 2023
  • ASRT 1997
  • Fundamental
  • Price
  • GNLX $4.31
  • ASRT $0.80
  • Analyst Decision
  • GNLX Strong Buy
  • ASRT Strong Buy
  • Analyst Count
  • GNLX 4
  • ASRT 4
  • Target Price
  • GNLX $18.25
  • ASRT $3.19
  • AVG Volume (30 Days)
  • GNLX 312.3K
  • ASRT 362.1K
  • Earning Date
  • GNLX 03-31-2025
  • ASRT 03-10-2025
  • Dividend Yield
  • GNLX N/A
  • ASRT N/A
  • EPS Growth
  • GNLX N/A
  • ASRT N/A
  • EPS
  • GNLX N/A
  • ASRT N/A
  • Revenue
  • GNLX $8,000.00
  • ASRT $125,763,000.00
  • Revenue This Year
  • GNLX N/A
  • ASRT N/A
  • Revenue Next Year
  • GNLX N/A
  • ASRT $1.84
  • P/E Ratio
  • GNLX N/A
  • ASRT N/A
  • Revenue Growth
  • GNLX N/A
  • ASRT N/A
  • 52 Week Low
  • GNLX $1.60
  • ASRT $0.73
  • 52 Week High
  • GNLX $9.79
  • ASRT $1.80
  • Technical
  • Relative Strength Index (RSI)
  • GNLX 75.11
  • ASRT 43.92
  • Support Level
  • GNLX $3.20
  • ASRT $0.78
  • Resistance Level
  • GNLX $4.23
  • ASRT $0.83
  • Average True Range (ATR)
  • GNLX 0.56
  • ASRT 0.03
  • MACD
  • GNLX 0.10
  • ASRT 0.00
  • Stochastic Oscillator
  • GNLX 95.73
  • ASRT 39.86

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: